Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Wolfreys A"" wg kryterium: Autor


Wyświetlanie 1-17 z 17
Tytuł :
Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in Humans.
Autorzy :
Holdsworth G; UCB Pharma, Slough, UK.
Staley JR; UCB Pharma, Slough, UK.
Hall P; UCB Pharma, Slough, UK.
van Koeverden I; University Medical Centre Utrecht, Utrecht, The Netherlands.
Vangjeli C; UCB Pharma, Slough, UK.
Okoye R; UCB Pharma, Slough, UK.
Boyce RW; Amgen Inc., Thousand Oaks, CA, USA.
Turk JR; Amgen Inc., Thousand Oaks, CA, USA.
Armstrong M; UCB Pharma, Braine-L'Alleud, Belgium.
Wolfreys A; UCB Pharma, Slough, UK.
Pasterkamp G; University Medical Centre Utrecht, Utrecht, The Netherlands.
Pokaż więcej
Źródło :
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research [J Bone Miner Res] 2021 Mar 19. Date of Electronic Publication: 2021 Mar 19.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
The use of emerging safety biomarkers in nonclinical and clinical safety assessment - The current and future state: An IQ DruSafe industry survey.
Autorzy :
Zabka TS; Genentech Inc, 1 DNA Way, South San Francisco, CA, USA. Electronic address: .
Burkhardt J; Pfizer, 1 Eastern Point Road, Groton, CT, USA. Electronic address: .
Reagan WJ; Pfizer, 1 Eastern Point Road, Groton, CT, USA. Electronic address: .
Gautier JC; Sanofi, 13, Quai Jules Guesde, Vitry-sur-Seine, France. Electronic address: .
Glaab WE; Merck & Co, 770 Sumneytown Pike, West Point, PA, USA. Electronic address: .
Guffroy M; AbbVie, 1 North Waukegan Road, North Chicago, IL, USA. Electronic address: .
Harding J; AstraZeneca, Da Vinci Building, Melbourn Science Park, Cambridge Road, Melbourn, Royston, Hertfordshire, UK. Electronic address: .
Brees D; Novartis, 4057 Basel, Basel-stadt, Switzerland. Electronic address: .
McDuffie E; Janssen, 3210 Merryfield Row, San Diego, CA, USA. Electronic address: .
Ramaiah L; Pfizer, 401 North Middletown Road, Pearl River, NY, USA. Electronic address: .
Schultze AE; Lilly Research Laboratories, 893 S Delaware St, Indianapolis, IN, USA. Electronic address: .
Smith JD; Boehringer Ingelheim, 900 Ridgebury Rd, Ridgefield, CT, USA. Electronic address: .
Wolfreys A; UCB Biopharma, Bath Road, Slough, Berkshire, UK. Electronic address: alison.wolfreys@ucb.com.
Dalmas DA; GlaxoSmithKline, 1250 S. Collegeville Rd, Collegeville, PA, USA. Electronic address: deidre.a..
Pokaż więcej
Źródło :
Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2021 Mar; Vol. 120, pp. 104857. Date of Electronic Publication: 2020 Dec 31.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Review of the Technical, Toxicological, and PKPD Considerations for Conducting Inhalation Toxicity Studies on Biologic Pharmaceuticals-The Outcome of a Cross-Industry Working Group Survey.
Autorzy :
Wolfreys A; 439704UCB Biopharma, Slough, United Kingdom.
Kilgour J; 273049Regulatory Science Associates, Inverkip, United Kingdom.
Allen AD; 18869Chiesi Farmaceutici S.p.A., Parma, Italy.
Dudal S; 1529Roche Innovation Centre, Basel, Switzerland.
Freke M; Charles River Laboratories, Montreal, Canada.
Jones D; 9059MHRA, London, United Kingdom.
Karantabias G; GSK, Collegeville, PA, USA.
Krantz C; Novartis, Basel, Switzerland.
Moore S; Covance, Huntingdon, United Kingdom.
Mukaratirwa S; Covance, Huntingdon, United Kingdom.
Price M; GSK, Ware, United Kingdom.
Tepper J; Tepper Nonclinical Consulting, San Carlos, CA, USA.
Cauvin A; UCB Biopharma Srl, Braine-L'Alleud, Belgium.
Manetz S; AstraZeneca, Cambridge, USA.
Robinson I; Astrazeneca, Royston, United Kingdom.
Pokaż więcej
Źródło :
Toxicologic pathology [Toxicol Pathol] 2021 Feb; Vol. 49 (2), pp. 261-285. Date of Electronic Publication: 2021 Feb 03.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
BSTP Review of 12 Case Studies Discussing the Challenges, Pathology, Immunogenicity, and Mechanisms of Inhaled Biologics.
Autorzy :
Hall AP; UCB BioPharma, Slough, United Kingdom.
Tepper JS; Tepper Nonclinical Consulting, San Carlos, CA, USA.
Boyle MH; 201915Covance Inc., Somerset, NJ, USA.
Cary MG; Pathology Experts GmbH, Witterswil, Switzerland.
Flandre TG; 98560Novartis Institutes for Biomedical Research, Basel, Switzerland.
Piaia A; 98560Novartis Institutes for Biomedical Research, Basel, Switzerland.
Tarnow I; Savara Pharmaceuticals, Hørsholm, Denmark.
Macri NP; Tepper Nonclinical Consulting, San Carlos, CA, USA.
Freke MC; 70294Charles River Laboratories Montreal ULC, Senneville, Quebec, Canada.
Nikula KJ; Inotiv, Maryland Heights, MO, USA.
Paul GR; 1929GlaxoSmithKline, Ware, United Kingdom.
Cauvin A; UCB BioPharma SRL, Braine L'Alleud, Belgium.
Gregori M; Covance, Huntingdon, United Kingdom.
Haworth R; 1929GlaxoSmithKline, Ware, United Kingdom.
Naylor S; Charles River Laboratories, Edinburgh, United Kingdom.
Price M; 1929GlaxoSmithKline, Ware, United Kingdom.
Robinson IN; 4625AstraZeneca, Melbourn, United Kingdom.
Allen A; 18869Chiesi Farmaceutici S.p.A., Parma, Italy.
Gelzleichter T; Genentech Inc., South San Francisco, CA, USA.
Hohlbaum AM; Sanofi, Zwijnaarde, Belgium.
Manetz S; AstraZeneca, Gaithersburg, MD, USA.
Wolfreys A; UCB BioPharma, Slough, United Kingdom.
Colman K; 70089Genomics Institute for the Novartis Research Foundation, San Diego, CA, USA.
Fleurance R; UCB BioPharma SRL, Braine L'Alleud, Belgium.
Jones D; 9059MHRA, London, United Kingdom.
Mukaratirwa S; Covance, Huntingdon, United Kingdom.
Pokaż więcej
Źródło :
Toxicologic pathology [Toxicol Pathol] 2021 Feb; Vol. 49 (2), pp. 235-260. Date of Electronic Publication: 2021 Jan 18.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Justification for species selection for pharmaceutical toxicity studies.
Autorzy :
Prior H; National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), 215 Euston Rd, London, NW1 2BE, UK.
Haworth R; GlaxoSmithKline R&D, Park Road, Ware, SG12 0DP, UK.
Labram B; National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), 215 Euston Rd, London, NW1 2BE, UK.
Roberts R; ApconiX, Alderley Park, Alderley Edge, SK10 4TG, UK.
Wolfreys A; UCB Biopharma, Bath Rd, Slough, SL1 3WE, UK.
Sewell F; National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), 215 Euston Rd, London, NW1 2BE, UK.
Pokaż więcej
Źródło :
Toxicology research [Toxicol Res (Camb)] 2020 Nov 24; Vol. 9 (6), pp. 758-770. Date of Electronic Publication: 2020 Nov 24 (Print Publication: 2020).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture.
Autorzy :
Turk JR; Translational Safety and Bioanalytical Sciences, Amgen Research, Thousand Oaks, CA, USA. Electronic address: .
Deaton AM; Translational Safety and Bioanalytical Sciences, Amgen Research, Cambridge, MA, USA.
Yin J; Genome Analysis Unit, Amgen Research, South San Francisco, CA, USA.
Stolina M; Cardiometabolic Disorders Research, Amgen Research, Thousand Oaks, CA, USA.
Felx M; Charles River Laboratories Montreal ULC, Senneville, QC, Canada.
Boyd G; Charles River Laboratories Montreal ULC, Senneville, QC, Canada.
Bienvenu JG; Charles River Laboratories Montreal ULC, Senneville, QC, Canada.
Varela A; Charles River Laboratories Montreal ULC, Senneville, QC, Canada.
Guillot M; Charles River Laboratories Montreal ULC, Senneville, QC, Canada.
Holdsworth G; UCB Pharma, Slough, UK.
Wolfreys A; UCB Pharma, Slough, UK.
Dwyer D; Cardiometabolic Disorders Research, Amgen Research, Thousand Oaks, CA, USA.
Kumar SV; Translational Safety and Bioanalytical Sciences, Amgen Research, Cambridge, MA, USA.
de Koning EM; Translational Safety and Bioanalytical Sciences, Amgen Research, Cambridge, MA, USA.
Qu Y; Translational Safety and Bioanalytical Sciences, Amgen Research, Thousand Oaks, CA, USA.
Engwall M; Translational Safety and Bioanalytical Sciences, Amgen Research, Thousand Oaks, CA, USA.
Locher K; Translational Safety and Bioanalytical Sciences, Amgen Research, South San Francisco, CA, USA.
Ward LD; Translational Safety and Bioanalytical Sciences, Amgen Research, Cambridge, MA, USA.
Glaus C; Cardiometabolic Disorders Research, Amgen Research, Thousand Oaks, CA, USA.
He YD; Translational Safety and Bioanalytical Sciences, Amgen Research, Thousand Oaks, CA, USA; Genome Analysis Unit, Amgen Research, South San Francisco, CA, USA.
Boyce RW; Translational Safety and Bioanalytical Sciences, Amgen Research, Thousand Oaks, CA, USA.
Pokaż więcej
Źródło :
Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2020 Aug; Vol. 115, pp. 104697. Date of Electronic Publication: 2020 Jun 23.
Typ publikacji :
Journal Article
MeSH Terms :
Adaptor Proteins, Signal Transducing/*antagonists & inhibitors
Antibodies, Monoclonal/*pharmacology
Bone Density Conservation Agents/*pharmacology
Cardiovascular System/*drug effects
Animals ; Antibodies, Monoclonal/therapeutic use ; Bone Density Conservation Agents/therapeutic use ; Drug Evaluation, Preclinical ; Female ; Fractures, Bone/prevention & control ; Humans ; Macaca fascicularis ; Male ; Mice, Inbred C57BL ; Mice, Knockout, ApoE ; Osteoporosis/drug therapy ; Rats, Sprague-Dawley ; Risk
Czasopismo naukowe
Tytuł :
Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluation.
Autorzy :
Prior H; National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), Gibbs Building, 215 Euston Road, London, NW1 2BE, UK. Electronic address: .
Baldrick P; Covance Laboratories Ltd, Otley Road, Harrogate, HG3 1PY, UK.
Beken S; Federal Agency for Medicines and Health Products (FAMHP), Victor Hortaplace 40/40, Brussels, 1060, Belgium.
Booler H; Genentech, Inc, 1 DNA Way, South San Francisco, CA, 94080, USA.
Bower N; Eisai Inc, 155 Tice Blvd, Woodcliff Lake, NJ, 07677, USA.
Brooker P; Board member, NC3Rs, Gibbs Building, 215 Euston Road, London, NW1 2BE, UK.
Brown P; Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
Burlinson B; Covance, Huntingdon, Cambridgeshire, PE28 4HS, UK.
Burns-Naas LA; Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA, 94404, USA.
Casey W; National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), National Institute of Environmental Health Sciences, P.O. Box 12233, Research Triangle Park, NC, 27709, USA.
Chapman M; Oncology Safety, Clinical Pharmacology and Safety Sciences,R&D, AstraZeneca, Cambridge, UK.
Clarke D; Lilly Research Laboratories, Indianapolis, IN, 46285, USA.
de Haan L; Biologics and Advanced Therapeutics Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
Doehr O; Bayer Pharma AG, Müllerstrasse 170, 13353, Berlin, Germany.
Downes N; Sequani Limited, Bromyard Rd, Ledbury, Herefordshire, HR8 1LH, UK.
Flaherty M; Takeda Pharmaceuticals, 300 Massachusetts Ave, Cambridge, MA, 02139, USA.
Gellatly N; National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), Gibbs Building, 215 Euston Road, London, NW1 2BE, UK.
Moesgaard SG; Novo Nordisk A/S, Novo Nordisk Park, Maaloev, Denmark.
Harris J; Association of British Pharmaceutical Industry (ABPI), 105 Victoria Street, London, SW1E 6QT, UK.
Holbrook M; VAST Pharma Solutions Ltd, Harrogate, UK.
Hui J; Celgene, 86 Morris Avenue, Summit, NJ, 07901, USA.
Jones D; Medicines Healthcare products Regulatory Agency (MHRA) 10 South Colonnade, Canary Wharf, London, E14 4PU, UK.
Jones K; CFMD Ltd, Peterborough, UK.
Kedar H; Teva Pharmaceuticals, Netanya Area, Israel.
Mahl A; Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Manninen A; Prekliniska Byran Sweden AB, Stockholm, Sweden.
McGuire A; Charles River Laboratories, Preclinical Services, Tranent, Edinburgh, EH33 2NE, UK.
Mortimer-Cassen E; Regulatory Safety Centre of Excellence, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
Peraza M; Pfizer Drug Safety Research and Development, 300 Technology Square, Cambridge, MA, 02139, USA.
Pugsley MK; Cytokinetics, South San Francisco, CA, 94080, USA.
Richard J; Sanofi, 371 Rue du Professeur Blayac, Montpellier, 34000, France.
Roberts R; ApconiX, Alderley Park, Alderley Edge, Cheshire, SK10 4TG, UK.
Roosen W; Janssen Research & Development, Turnhoutseweg 30, 2340, Beerse, Belgium.
Rothfuss A; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, CH - 4070, Basel, Switzerland.
Schoenmakers A; Charles River Laboratories, Den Bosch B.V, the Netherlands.
Sewell F; National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), Gibbs Building, 215 Euston Road, London, NW1 2BE, UK.
Weaver R; Institut de Recherches Internationales Servier, Biopharmacy, 92284, Suresnes, Cedex, France.
Weir L; GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 0DP, UK.
Wolfreys A; UCB Biopharma, Bath Rd, Slough, SL1 3WE, UK.
Kimber I; University of Manchester, Faculty of Biology, Medicine and Health, Oxford Rd, Manchester, M13 9PL, UK.
Pokaż więcej
Źródło :
Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2020 Jun; Vol. 113, pp. 104624. Date of Electronic Publication: 2020 Feb 29.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Development*
Toxicity Tests*
Drug Evaluation, Preclinical/*adverse effects
Animals ; Databases, Factual ; Humans ; Risk Assessment
Czasopismo naukowe
Tytuł :
Identification of a Novel Allosteric Inhibitory Site on Tryptophan Hydroxylase 1 Enabling Unprecedented Selectivity Over all Related Hydroxylases.
Autorzy :
Petrassi M; Genomics Institute of the Novartis Research Foundation, San DiegoCA, USA.
Barber R; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Be C; Novartis Institutes for BioMedical ResearchBasel, Switzerland.
Beach S; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Cox B; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
D'Souza AM; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Duggan N; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Hussey M; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Fox R; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Hunt P; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Jarai G; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Kosaka T; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Oakley P; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Patel V; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Press N; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Rowlands D; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Scheufler C; Novartis Institutes for BioMedical ResearchBasel, Switzerland.
Schmidt O; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Srinivas H; Novartis Institutes for BioMedical ResearchBasel, Switzerland.
Turner M; Genomics Institute of the Novartis Research Foundation, San DiegoCA, USA.
Turner R; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Westwick J; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Wolfreys A; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Pathan N; Genomics Institute of the Novartis Research Foundation, San DiegoCA, USA.
Watson S; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.
Thomas M; Respiratory Disease Area, Novartis Institutes for BioMedical ResearchHorsham, UK.; Translational Biology, Respiratory, Inflammation and Autoimmunity IMED, AstraZenecaGothenburg, Sweden.
Pokaż więcej
Źródło :
Frontiers in pharmacology [Front Pharmacol] 2017 May 05; Vol. 8, pp. 240. Date of Electronic Publication: 2017 May 05 (Print Publication: 2017).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.
Autorzy :
Brennan FR; Preclinical Safety, New Medicines, UCB-Celltech, Slough, SL1 3WE, UK.
Cauvin A
Tibbitts J
Wolfreys A
Pokaż więcej
Źródło :
Drug development research [Drug Dev Res] 2014 May; Vol. 75 (3), pp. 115-61. Date of Electronic Publication: 2014 Apr 29.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Anti-Inflammatory Agents*/adverse effects
Anti-Inflammatory Agents*/pharmacology
Anti-Inflammatory Agents*/therapeutic use
Antibodies, Monoclonal*/adverse effects
Antibodies, Monoclonal*/pharmacology
Antibodies, Monoclonal*/therapeutic use
Immunologic Factors*/adverse effects
Immunologic Factors*/pharmacology
Immunologic Factors*/therapeutic use
Animals ; Drug Evaluation, Preclinical/methods ; Humans ; Inflammation/drug therapy
Czasopismo naukowe
Tytuł :
Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses.
Autorzy :
Forbes B; Academy of Pharmaceutical Sciences of Great Britain, UK; King's College London, Institute of Pharmaceutical Science, London SE1 9NH, UK.
O'Lone R; Health and Environmental Sciences Institute, USA.
Allen PP; GlaxoSmithKline R & D, Gunnels Wood Road, Stevenage SG1 2NY, UK.
Cahn A; GlaxoSmithKline R & D, Gunnels Wood Road, Stevenage SG1 2NY, UK.
Clarke C; Amgen, USA.
Collinge M; Pfizer R & D, USA.
Dailey LA; King's College London, Institute of Pharmaceutical Science, London SE1 9NH, UK.
Donnelly LE; Imperial College London, UK.
Dybowski J; Pfizer R & D, USA.
Hassall D; GlaxoSmithKline R & D, Gunnels Wood Road, Stevenage SG1 2NY, UK.
Hildebrand D; GlaxoSmithKline R & D, Gunnels Wood Road, Stevenage SG1 2NY, UK.
Jones R; Pfizer R & D, USA.
Kilgour J; AstraZeneca R & D, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.
Klapwijk J; GlaxoSmithKline R & D, Gunnels Wood Road, Stevenage SG1 2NY, UK.
Maier CC; GlaxoSmithKline R & D, USA.
McGovern T; SciLucent LLC, 585 Grove Street, Herndon, VA 20170, USA.
Nikula K; Seventh Wave Laboratories, USA.
Parry JD; GlaxoSmithKline R & D, Gunnels Wood Road, Stevenage SG1 2NY, UK.
Reed MD; Lovelace Respiratory Research Institute, USA.
Robinson I; AstraZeneca R & D, Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
Tomlinson L; Pfizer R & D, USA.
Wolfreys A; Novartis Horsham Research Centre, Horsham RH12 5AB, UK.
Pokaż więcej
Źródło :
Advanced drug delivery reviews [Adv Drug Deliv Rev] 2014 May; Vol. 71, pp. 15-33. Date of Electronic Publication: 2014 Feb 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Delivery Systems*
Drug Design*
Macrophages, Alveolar/*metabolism
Administration, Inhalation ; Aerosols ; Animals ; Biomarkers/metabolism ; Drug Discovery/methods ; Drug-Related Side Effects and Adverse Reactions/prevention & control ; Humans ; Risk Assessment/methods ; Toxicity Tests/methods
Czasopismo naukowe
Tytuł :
Approaches to the risk assessment of genotoxic carcinogens in food: a critical appraisal.
Autorzy :
O'Brien J; Food Safety Authority of Ireland, Abbey Court, Lower Abbey Street, Dublin 1, Ireland.
Renwick AG
Constable A
Dybing E
Müller DJ
Schlatter J
Slob W
Tueting W
van Benthem J
Williams GM
Wolfreys A
Pokaż więcej
Źródło :
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association [Food Chem Toxicol] 2006 Oct; Vol. 44 (10), pp. 1613-35. Date of Electronic Publication: 2006 Jul 14.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Carcinogenicity Tests/*methods
Carcinogens/*toxicity
Food/*toxicity
Mutagenicity Tests/*methods
Mutagens/*toxicity
Animals ; Carcinogens/pharmacokinetics ; Dose-Response Relationship, Drug ; Food/standards ; Food Additives/toxicity ; Food Contamination ; Humans ; Neoplasms, Experimental/chemically induced ; Neoplasms, Experimental/genetics ; Risk Assessment
Czasopismo naukowe
Tytuł :
Association of gene expression with sequential proliferation, differentiation and tumor formation in murine skin.
Autorzy :
Ridd K; MRC Toxicology Unit, University of Leicester, Leicester, LE1 9HN, UK.
Zhang SD
Edwards RE
Davies R
Greaves P
Wolfreys A
Smith AG
Gant TW
Pokaż więcej
Źródło :
Carcinogenesis [Carcinogenesis] 2006 Aug; Vol. 27 (8), pp. 1556-66. Date of Electronic Publication: 2006 Mar 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cell Differentiation*
Cell Proliferation*
Gene Expression Regulation, Neoplastic*
Biomarkers/*metabolism
Skin Neoplasms/*genetics
9,10-Dimethyl-1,2-benzanthracene/toxicity ; Animals ; Carcinogens/toxicity ; Cell Transformation, Neoplastic/genetics ; Female ; Gene Expression Profiling ; Genes, ras ; Humans ; Mice ; Mice, Transgenic ; Oligonucleotide Array Sequence Analysis ; Papilloma/chemically induced ; Papilloma/genetics ; Papilloma/pathology ; Reverse Transcriptase Polymerase Chain Reaction ; Skin/drug effects ; Skin/metabolism ; Skin Neoplasms/chemically induced ; Skin Neoplasms/pathology ; Tetradecanoylphorbol Acetate/toxicity
Czasopismo naukowe
Tytuł :
Safety evaluation of phytosterol esters. Part 8. Lack of genotoxicity and subchronic toxicity with phytosterol oxides.
Autorzy :
Lea LJ; Safety & Environmental Assurance Centre, Unilever Colworth, Sharnbrook, Bedford MK44 1LQ, UK. />Hepburn PA
Wolfreys AM
Baldrick P
Pokaż więcej
Źródło :
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association [Food Chem Toxicol] 2004 May; Vol. 42 (5), pp. 771-83.
Typ publikacji :
Journal Article
MeSH Terms :
Chromosome Aberrations/*chemically induced
Oxides/*toxicity
Phytosterols/*toxicity
Administration, Oral ; Animals ; Body Weight/drug effects ; Consumer Product Safety ; Dose-Response Relationship, Drug ; Eating/drug effects ; Esters ; Female ; Male ; Micronucleus Tests ; Mutagenicity Tests ; No-Observed-Adverse-Effect Level ; Oxidation-Reduction ; Random Allocation ; Rats ; Rats, Wistar ; Risk Assessment ; Salmonella typhimurium/drug effects ; Toxicity Tests
Czasopismo naukowe
Tytuł :
Safety evaluation of ice-structuring protein (ISP) type III HPLC 12 preparation. Lack of genotoxicity and subchronic toxicity.
Autorzy :
Hall-Manning T; Safety and Environmental Assurance Centre, Unilever Colworth, Colworth House, Bedfordshire MK44 1LQ, Sharnbrook, UK. />Spurgeon M
Wolfreys AM
Baldrick AP
Pokaż więcej
Źródło :
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association [Food Chem Toxicol] 2004 Feb; Vol. 42 (2), pp. 321-33.
Typ publikacji :
Journal Article
MeSH Terms :
Antifreeze Proteins, Type III/*toxicity
Food Preservatives/*toxicity
Administration, Oral ; Animals ; Antifreeze Proteins, Type III/administration & dosage ; Bone Marrow/drug effects ; Cell Line, Tumor/drug effects ; Chromosome Aberrations/drug effects ; Female ; Food Preservatives/administration & dosage ; Intubation, Gastrointestinal ; Male ; Mice ; Micronucleus Tests ; Mutagenicity Tests ; Rats ; Rats, Wistar ; Salmonella typhimurium/drug effects
Czasopismo naukowe
Tytuł :
Safety evaluation of phytosterol esters. Part 7. Assessment of mutagenic activity of phytosterols, phytosterol esters and the cholesterol derivative, 4-cholesten-3-one.
Autorzy :
Wolfreys AM; SEAC-Safety and Environmental Assurance Centre, Unilever Laboratory Colworth, Sharnbrook, MK44 1LQ, Bedford, UK. alison.wolfreys@unilever.com
Hepburn PA
Pokaż więcej
Źródło :
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association [Food Chem Toxicol] 2002 Apr; Vol. 40 (4), pp. 461-70.
Typ publikacji :
Journal Article
MeSH Terms :
Cholestenones/*adverse effects
Chromosome Aberrations/*chemically induced
Phytosterols/*adverse effects
Animals ; Bone Marrow ; DNA/biosynthesis ; Escherichia coli/drug effects ; Esters/adverse effects ; Liver/pathology ; Male ; Micronucleus Tests ; Mutagenicity Tests ; Rats ; Salmonella typhimurium/drug effects
Czasopismo naukowe
Tytuł :
Frequencies of hprt(-) mutations and bcl-2 translocations in circulating human lymphocytes are correlated with United Kingdom sunlight records.
Autorzy :
Bentham G; Centre for Environmental Risk, School of Environmental Sciences, University of East Anglia, Norwich NR4 7TJ, UK. />Wolfreys AM
Liu Y
Cortopassi G
Green MH
Arlett CF
Cole J
Pokaż więcej
Źródło :
Mutagenesis [Mutagenesis] 1999 Nov; Vol. 14 (6), pp. 527-32.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
MeSH Terms :
Mutation*/genetics
Mutation*/radiation effects
Sunlight*/adverse effects
Genes, bcl-2/*radiation effects
Hypoxanthine Phosphoribosyltransferase/*genetics
Lymphocytes/*radiation effects
Translocation, Genetic/*radiation effects
Databases, Factual ; Genes, bcl-2/genetics ; Humans ; Lymphoma, Non-Hodgkin/metabolism ; Population Surveillance/methods ; Translocation, Genetic/genetics ; Ultraviolet Rays/adverse effects ; United Kingdom/epidemiology
Czasopismo naukowe
Tytuł :
The ability of the Comet assay to discriminate between genotoxins and cytotoxins.
Autorzy :
Henderson L; Environmental Safety Laboratory, Unilever Research, Sharnbrook, UK. />Wolfreys A
Fedyk J
Bourner C
Windebank S
Pokaż więcej
Źródło :
Mutagenesis [Mutagenesis] 1998 Jan; Vol. 13 (1), pp. 89-94.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cytotoxins/*toxicity
Electrophoresis, Agar Gel/*methods
Mutagens/*toxicity
4-Nitroquinoline-1-oxide/toxicity ; Aminacrine/toxicity ; Animals ; Cell Extracts/genetics ; Cell Line ; Cell Survival/drug effects ; DNA/drug effects ; Ethyl Methanesulfonate/toxicity ; Ethylnitrosourea/toxicity ; Glyoxal/toxicity ; Humans ; Hydrogen Peroxide/toxicity ; Mitomycin/toxicity
Czasopismo naukowe
    Wyświetlanie 1-17 z 17

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies